International Clinical Trial: A randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pichia) administered in people aged 6 weeks to 13 years

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114809) titled 'A randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to evaluate the protective efficacy, immunogenicity, and safety of quadrivalent recombinant norovirus vaccine (Pichia Pichia) administered in people aged 6 weeks to 13 years' on Dec. 17, 2025.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Guangxi Center for Disease Prevention and Control

Condition: Acute Gastroenteritis caused by norovirus infection

Intervention: Control group:Three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo were administered 30 days apart

Recr...